Saturable active tubular reabsorption in the renal clearance of mesalazine in human volunteers

Clinical Drug Investigation

Volumn 20, Issue 1, 2000, Pages 35-42

  Vree, Tom B ^a   Dammers, Erik ^b   Exler, Peter S ^c   Sörgel, Fritz ^d   Maes, Robert A A ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DADA Consultancy   (Netherlands)

^c Disphar International   (Netherlands)

^d Institute for Biomedical Research   (Germany)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; SALICYLIC ACID DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG RELEASE; DRUG SOLUBILITY; DRUG URINE LEVEL; FEMALE; GLOMERULUS FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033909978     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020010-00005     Document Type: Article

References (26)

1. 1. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98 (5 Pt 1): 1162-9
2. 2. Prakash A, Markham A. Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease. Drugs 1999; 57: 383-408
3. 3. Martindale. Reynolds JEF, editor. The extra pharmacopoeia. 31st ed. Gastro-intestinal agents. Mesalazine. London: Pharmaceutical Press, 1996: 1227-8
4. 4. Yu DK, Morrill B, Eichmeier LS, et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Eur J Clin Pharmacol 1995; 48: 273-7
5. 5. Norlander B, Gotthard R, Ström M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers. Aliment Pharmacol Ther 1990; 4: 497-505
6. 6. Bondesen S, Hegnhoj J, Larsen F, et al. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. Dig Dis Sci 1991; 36: 1735-40
7. 7. Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989; 38: 500-23
8. 8. Järnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 1989; 37: 73-6
9. 9. Meyers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of mesalazine in healthy volunteers given intravenously or released for absorption at different sites in the gastro-intestinal tract. Gut 1987; 28: 196-200
10. 10. Allgayer H, Sonnenbichler J, Kruis W, et al. Determination of the pK values of 5-aminosalicylic acid and N-acetylsalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites. Arzneimittelforschung 1985; 35: 1457-9
11. 11. Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal installation in man. Br J Clin Pharmacol 1983; 16: 738-40
12. 12. Jacobsen BA, Abildgaard K, Rasmussen HH, et al. Availability of mesalazine from enemas and suppositories during steady state conditions. Scand J Gastroenterol 1991; 26: 374-8
13. 13. Vree TB, Dammers E, Exler PS, et al. Mono and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in 24 healthy male volunteers controlled by the time of defecation before dosing. J Pharm Pharmacol 2000. In press
14. 14. Yu DK, Elvin AT, Morrill B, et al. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. Clin Pharmacol Ther 1990; 48: 26-33
15. 15. Norlander B, Gotthard R, Ström M. Steady-state pharmacokinetics of enteric coated 5-aminosalicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther 1991; 5: 291-300
16. 16. Gionchetti P, Campieri M, Belluzzi A, et al. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers. Aliment Pharmacol Ther 1994; 8: 535-40
17. 4-acetylsulphamethoxazole. Clin Pharmacokinet 1978; 3: 319-29
18. 18. Vree TB, van Ewijk-Beneken Kolmer EWJ, Verwey-Van Wissen CPWM, et al. Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. Int J Clin Pharmacol Ther 1994; 32: 550-8
19. 4-acetyl metabolites of sulphasomidine and sulphadimethoxine in the dog. J Pharm Pharmacol 1993; 45: 614-7
20. 20. Boom SP, Hoet S, Russel FG. Saturable urinary excretion kinetics of famotidine in the dog. J Pharm Pharmacol 1997; 49: 288-92
21. 21. Boom SP, Meyer I, Wouterse AC, et al. A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. Biopharm Drug Dispos 1998; 19: 199-208
22. 22. Bondesen S, Rasmussen SN, Rask-Madsen J, et al. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease. Acta Med Scand 1987; 221: 227-42
23. 23. Diener U, Tuczek HV, Fischer C, et al. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol 1984; 326: 278-82
24. 24. Calder IC, Funder CC, Gree CR, et al. Nephrotoxic lesions from 5-aminosalicylic acid. BMJ 1972; 1: 152-4
25. 25. Noble E, Janssen L, Dierickx PJ. Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines. Cell Biol Toxicol 1997; 13: 445-51
26. 26. Fraser JS, Smith D, Lamb E, et al. Prospective study of the effect of 5-aminosalicylic acid (mesalazine) on renal function in inflammatory bowel disease [abstract no. 4377]. Proceedings Digestive Disease Week. 1999 May 16-19; Orlando, Florida, USA; 1999: A-794-5